logo-loader

Amryt Pharma's Dr Helen Phillips on 'remarkable' real-world Lojuxta study

Published: 15:58 28 Apr 2017 BST

Amryt Pharma PLC (LON:AMYT) currently has an exclusive licence to sell Lojuxta to adults in the EU and other territories including the Middle East, North Africa, Turkey and Israel.

Dr Helen Phillips, their head of medical affairs, talks through with Proactive's Andrew Scott their 'unexpected and exciting' findings from a real world study that's been done on the cholesterol-lowering drug.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 28 minutes ago